Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis-authors' reply.

Autor: Safadi R; The Liver Unit. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel., Braun M; The Liver Institute, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel., Francis A; Cardiology Department, Holy Family Hospital, Nazareth, Israel., Milgrom Y; The Liver Unit. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel., Massarwa M; The Liver Unit. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel., Hakimian D; The Liver Unit. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel., Hazou W; The Liver Unit. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel., Issachar A; The Liver Institute, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel., Harpaz Z; Can-Fite BioPharma Ltd, Petah-Tikva, Israel., Farbstein M; Can-Fite BioPharma Ltd, Petah-Tikva, Israel., Itzhak I; Can-Fite BioPharma Ltd, Petah-Tikva, Israel., Lev-Cohain N; The Radiology Dep. Hadassah Medical Organization, Hadassah Hebrew University Medical Centre, Jerusalem, Israel., Bareket-Samish A; BioInsight Ltd, Binyamina, Israel., Silverman MH; Can-Fite BioPharma Ltd, Petah-Tikva, Israel., Fishman P; Can-Fite BioPharma Ltd, Petah-Tikva, Israel.
Jazyk: angličtina
Zdroj: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Feb; Vol. 55 (4), pp. 485-486.
DOI: 10.1111/apt.16762
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje